Panama’s medical cannabis program is tightly regulated and still in its early stages. Here is what you need to know.
Qualifying conditions: As noted above, conditions reported across official and legal sources include epilepsy, chronic pain, cancer, Alzheimer’s disease, autism, HIV/AIDS, arthritis, multiple sclerosis, chemotherapy-related nausea and vomiting, glaucoma, Crohn’s disease, ALS, muscular spasms, fibromyalgia, neuropathic pain, and oncologic pain. The full official list may be broader, and the program may evolve as regulations develop.
For those interested in strains used medicinally elsewhere, check out Herb’s guide to medical marijuana strains.
How prescriptions work: CBD-based products require a standard medical prescription from any licensed physician certified by the Ministry of Health. THC-based products require a special controlled-substance prescription, similar to the class used for opioid medications, and are reserved for complex conditions like refractory epilepsy and multiple sclerosis.
Available product forms: Products include oils, creams, and tablets (CBD formulations), as well as restricted THC formulations for specific conditions. Reporting on Panama’s medical framework indicates that treatment may also be administered in vaporized or inhaled form using dry flower and approved medical devices, as distinct from smoking.
The patient registry: Patients may need to enroll in El Programa Nacional para el Estudio y Uso Medicinal del Cannabis (the National Program for the Study and Use of Medicinal Cannabis), a government-run registry that tracks medical cannabis patients and their prescriptions. However, early reporting on the first pharmacy suggested that the initial CBD phase could be accessed with a prescription without full registry enrollment, while THC products would later require tighter controls and registry linkage. The exact requirements may still be evolving.